A5055388658- Neuroscience of respiration and sleep
- Prenatal Substance Exposure Effects
- Infant Development and Preterm Care
- Maternal Mental Health During Pregnancy and Postpartum
- Neonatal skin health care
- Neonatal Health and Biochemistry
- Birth, Development, and Health
- Wound Healing and Treatments
- Neonatal Respiratory Health Research
- Pressure Ulcer Prevention and Management
University of Cincinnati
2017-2023
University of Cincinnati Medical Center
2017-2023
Objective To develop a tool to predict the need for pharmacologic treatment of neonatal abstinence syndrome ( NAS ) within 36 hours from birth in infants at risk opioid withdrawal. Study Design Retrospective study born gestation ≥34 weeks with utero exposure opioids during two time periods January 2013 through October 2016. Period 1 was used predictive validation period 2. Birth weight, gestational age, four categories exposure, and individual scores 21 withdrawal symptoms Modified Finnegan...
We aimed to compare the outcomes of pharmacotherapy with either buprenorphine or methadone in infants treated for neonatal abstinence syndrome (NAS) secondary intrauterine exposure methadone. This is a multi-center, retrospective cohort study assess length treatment (LOT), hospital stay (LOS), and cumulative opioid between NAS utero Infants delivered at gestational age ≥35 weeks maternal history opioid-use disorder and/or urine drug screen positive methadone, postnatal as first-line...
Objective The timing of antenatal steroids (ANS) on short- and long-term effects newborn infants was evaluated. Study Design This study conducted at the University Cincinnati Medical Center Level-III Neonatal Intensive Care Unit by reviewing medical records all women with history ANS exposure from January 2015 to December 2018. We compared outcomes newborns delivered within ideal therapeutic window 24 hours 7 days (within [WW]) after administration those exposed outside (outside primary...